Growth & profitability
- Revenue has declined 43.6% per year over the past 5 years.
MNOV Financials MEDICINOVA INC
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $409657 | $12M | 0.0% | -3242.5% | 28.9% | 26.3% | -$10M | — | $31M |
| 2024 | — | $11M | — | — | 21.0% | 19.8% | -$11M | — | $40M |
| 2023 | $1M | $9M | 0.0% | -990.0% | 13.7% | 12.9% | -$7M | — | $51M |
| 2022 | — | -$14M | — | — | -20.0% | -19.0% | -$13M | — | $19M |
| 2021 | $4M | -$10M | 0.0% | -253.0% | -12.1% | -11.6% | -$9M | — | $71M |
| 2020 | — | -$14M | — | — | -19.4% | -18.4% | -$11M | — | $60M |
| 2019 | — | -$13M | — | — | -17.3% | -16.3% | -$9M | — | $64M |
| 2018 | — | -$15M | — | — | -20.1% | -19.0% | -$9M | — | $62M |
| 2017 | — | -$11M | — | — | -28.9% | -25.7% | — | — | $28M |
| 2016 | — | -$11M | — | — | -31.5% | -27.3% | -$7M | — | $24M |
| 2015 | — | -$9M | — | — | -27.0% | -23.3% | — | — | $22M |
| 2014 | — | -$9M | — | — | -41.8% | -33.7% | — | — | $12M |
| 2013 | — | -$4M | — | — | -15.8% | -13.6% | -$11M | — | $7M |
| 2013 | — | -$272M | — | — | -1269.7% | -1039.5% | -$219M | — | $11M |
| 2013 | — | -$270M | — | — | -1176.8% | -975.8% | -$217M | — | $12M |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $458439 | -$2M | 0.0% | -554.3% | -6.2% | -5.7% | -$2M | — | $25M |
| Mar '26 | $186984 | -$3M | 0.0% | -1516.6% | -6.6% | -6.1% | -$3M | — | $27M |
| Dec '25 | $151739 | -$3M | 0.0% | -2038.0% | -6.7% | -6.1% | -$2M | — | $31M |
| Sep '25 | $123319 | -$3M | 0.0% | -2741.7% | -6.9% | -6.4% | — | — | $33M |
| Jun '25 | $134599 | -$3M | 0.0% | -2679.9% | -7.0% | -6.6% | -$2M | — | $34M |
| Mar '25 | — | -$3M | — | — | -5.7% | -5.5% | -$4M | — | $37M |
| Dec '24 | — | -$3M | — | — | -5.4% | -5.0% | -$2M | — | $40M |
| Sep '24 | — | -$3M | — | — | -5.2% | -4.9% | -$2M | — | $42M |
| Jun '24 | — | -$3M | — | — | -4.6% | -4.4% | — | — | $44M |
| Mar '24 | — | -$3M | — | — | -4.6% | -4.4% | — | — | $47M |
| Dec '23 | $0 | -$2M | — | — | -3.3% | -3.1% | -$499038 | — | $51M |
| Sep '23 | $1M | -$723107 | 0.0% | -114.7% | -1.1% | -1.1% | -$1M | — | $52M |
| Jun '23 | — | -$3M | — | — | -4.4% | -4.2% | — | — | $53M |
| Mar '23 | — | -$3M | — | — | -4.3% | -4.1% | — | — | $55M |
| Dec '22 | — | -$3M | — | — | -4.3% | -4.0% | — | — | $19M |
| Sep '22 | — | -$4M | — | — | -5.0% | -4.7% | — | — | $53M |
| Jun '22 | — | -$4M | — | — | -5.3% | -5.0% | — | — | $65M |
| Mar '22 | — | -$3M | — | — | -4.2% | -4.0% | — | — | $68M |
| Dec '21 | $0 | -$2M | — | — | -2.5% | -2.4% | -$4M | — | $71M |
| Sep '21 | $37500 | -$4M | 0.0% | -9605.2% | -4.1% | -3.9% | -$3M | — | $75M |
Valuation over time
How the market has priced MNOV against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 8.2× (Jan '24) to 6.6× (Sep '26).
- The price-to-sales ratio has risen from 69.9× (Jan '24) to 194.0× (Sep '26).
P/E
P/S
Frequently asked questions
Is MNOV growing its revenue and profit?
Over the past 5 years, MEDICINOVA INC's revenue has declined 43.6% per year. These are computed facts, not advice.
How much debt does MNOV have?
As of FY2025, MEDICINOVA INC reported — of total debt against $31M of cash.
What is MNOV's profit margin?
In FY2025, gross margin was —, operating margin -3242.5%, and net margin 2928.8%.
What is MNOV's P/E ratio?
As of Sep '26, MEDICINOVA INC traded at a price-to-earnings ratio of about 6.6× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.